| Literature DB >> 32900772 |
Israt S Alam1, Federico Simonetta2, Lukas Scheller2, Aaron T Mayer3,4, Robert Negrin5, Sanjiv S Gambhir3,4, Surya Murty3,4, Ophir Vermesh3, Tomomi W Nobashi3, Juliane K Lohmeyer2, Toshihito Hirai2, Jeanette Baker2, Kenneth H Lau3.
Abstract
Graft-versus-host disease (GvHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), mediated primarily by donor T cells that become activated and attack host tissues. Noninvasive strategies detecting T-cell activation would allow for early diagnosis and possibly more effective management of HCT recipients. PET imaging is a sensitive and clinically relevant modality ideal for GvHD diagnosis, and there is a strong rationale for the use of PET tracers that can monitor T-cell activation and expansion with high specificity. The TNF receptor superfamily member OX40 (CD134) is a cell surface marker that is highly specific for activated T cells, is upregulated during GvHD, and mediates disease pathogenesis. We recently reported the development of an antibody-based activated T-cell imaging agent targeting OX40. In the present study, we visualize the dynamics of OX40 expression in an MHC-mismatch mouse model of acute GvHD using OX40-immunoPET. This approach enabled visualization of T-cell activation at early stages of disease, prior to overt clinical symptoms with high sensitivity and specificity. This study highlights the potential utility of the OX40 PET imaging as a new strategy for GvHD diagnosis and therapy monitoring. SIGNIFICANCE: OX40-immunoPET imaging is a promising noninvasive strategy for early detection of GvHD, capable of detecting signs of GvHD pathology even prior to the development of overt clinical symptoms. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32900772 PMCID: PMC8224961 DOI: 10.1158/0008-5472.CAN-20-1149
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701